Search results for "5300"

showing 3 items of 3 documents

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

"Table 1" of "Observation of orbitally excited B mesons"

1996

No description provided.

InclusiveE+ E- --> B*BAR XSIG/SIGE+ E- --> Z0E+ E- ScatteringIntegrated Cross SectionExclusive91.2E+ E- --> B*(5300) XCross Section
researchProduct

Peripheral Frequency of CD4+ CD28- Cells in Acute Ischemic Stroke: Relationship With Stroke Subtype and Severity Markers.

2015

CD4+ CD28− T cells also called CD28 null cells have been reported as increased in the clinical setting of acute coronary syndrome. Only 2 studies previously analyzed peripheral frequency of CD28 null cells in subjects with acute ischemic stroke but, to our knowledge, peripheral frequency of CD28 null cells in each TOAST subtype of ischemic stroke has never been evaluated. We hypothesized that CD4+ cells and, in particular, the CD28 null cell subset could show a different degree of peripheral percentage in subjects with acute ischemic stroke in relation to clinical subtype and severity of ischemic stroke. The aim of our study was to analyze peripheral frequency of CD28 null cells in subjects…

RiskAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaObservational Study5300Severity of Illness IndexArticleBrain IschemiaBrain ischemiaCD28 AntigensInternal medicineSeverity of illnessmedicineNull cellHumanscardiovascular diseasesStrokeAgedbusiness.industryCase-control studyCD28General MedicineFlow Cytometrymedicine.diseaseLymphocyte Subsetsstroke CD4+ CD28-CD4 Lymphocyte CountPeripheralStrokeCardiovascular DiseasesCase-Control StudiesPhysical therapyCardiologybusiness
researchProduct